trending Market Intelligence /marketintelligence/en/news-insights/trending/b8fxke9aukt2pquk27wadw2 content esgSubNav
In This List

CytRx closes $7M direct offering of common shares

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


CytRx closes $7M direct offering of common shares

CytRx Corp. closed its direct offering of 5.6 million common shares at $1.25 apiece to raise $7.0 million in gross proceeds.

The company received about $6.5 million in net proceeds from the offering.

CytRx plans to use the net proceeds for working capital and general corporate purposes, including possible new drug discovery activities and acquisitions or mergers.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Los Angeles, Calif.-based CytRx is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor.